Testing of specimens collected from live animals for pathogen detection has become increasingly important for the control and prevention of production-limiting diseases. Although the detection of a specific virus does not correlate perfectly with presence of clinical disease, the identification of specific viruses which animals are exposed to can help determine production management decisions. Nucleic acid detection assays, predominately realtime PCR, have become a routine and highly valued component of laboratory diagnosis, providing increased timeliness and reliability for detection of a wide range of animal pathogens. The accuracy and diagnostic sensitivity of nucleic acid-based methodologies are however impacted critically by the quality and integrity of the diagnostic specimens. Factors contributing to low-quality, non-representative diagnostic specimens often include microbial overgrowth and enzyme-induced degradation of nucleic acids ([@bib0005], [@bib0110], [@bib0055], [@bib0070]) which occur between the time of sample collection in the field and processing in the laboratory. This is of particular concern for veterinary diagnostics where animals, particularly wildlife and range animals such as sheep and cattle, are not located near a veterinary clinic, laboratory, or appropriate courier system. A variety of stabilizing agents and fixatives are available for the preservation of DNA and RNA, but for various reasons, including cost and complexity of use, they have not found wide application for collection and transport of veterinary diagnostic specimens. A commercial technology used initially to preserve DNA for long-term storage, has since been applied to stabilization of both RNA and DNA for use in forensic and diagnostic applications ([@bib0085], [@bib0075], [@bib0095]). The commercial product, FTA Cards™,[1](#fn0005){ref-type="fn"} is comprised of filter paper treated chemically, that when the biological specimen is applied to the paper, serves to lyse cells, denature proteins, and stabilize the nucleic acids. The nucleic acids in the specimen captured by and dried onto the FTA Card are protected from nucleases ([@bib0045]), oxidation, UV damage, and microbial overgrowth. Importantly, the stabilized specimen can be transported between the collection site and the laboratory without the need for a cold chain, liquid media handling concerns, time-sensitive shipping arrangements, or associated risk of disseminating an infectious agent. The FTA Card technology has been applied successfully to a range of tissues to capture and stabilize nucleic acids for subsequent testing, including human DNA ([@bib0025]), wildlife DNA ([@bib0090]), pathogen nucleic acids from plant specimens ([@bib0065]), and a range of human and animal pathogen nucleic acids, including from parasites, bacteria, and viruses. ([@bib0060], [@bib0080], [@bib0075], [@bib0040]).

The purpose of the current work was to verify the use of the FTA technology for collection and transport of diagnostic specimens used in the detection and identification of key viral pathogens associated with, or predisposing cattle to, Bovine Respiratory Disease (BRD) Complex ([@bib0030]) including bovine viral diarrhea virus (family flaviviridae, genus pestivirus, BVDV), bovine respiratory syncytial virus (family paramyxoviridae, subfamily penumovirinae, genus pneumovirus, BRSV), bovine coronavirus (family coronaviridae, genus coronavirus, BCoV), and bovine herpesvirus 1 (family herpesviridae, subfamily alphaherpesvirinae, BHV-1). Bovine Respiratory Disease was targeted specifically for this study as a disease syndrome impacting the beef cattle industry ([@bib0030]) and where early and reliable diagnosis is considered to be compromised due to the difficulty of collecting and submitting samples to the laboratory in a sufficiently suitable manner to fully insure the integrity and quality of the specimens. The FTA Card was considered an easy and reliable field-sampling and shipping option not requiring liquid handling, shelf-life sensitive laboratory media that must be pre-ordered or stored on-site by veterinary practitioners and producers, and having no requirements for cold storage. These characteristics are lacking for liquid media traditionally used, and thus the FTA Card approach offers an improvement in the practicality and feasibility of sampling from at-risk animals in the field, and in turn providing enhanced nucleic acid-based diagnostic and disease surveillance support for producers and practitioners in rural or remote environments.

The objective of the study was to verify that nucleic acids from specimens collected onto FTA Cards would be of equal or improved quality for PCR-based diagnosis ([@bib0035], [@bib0100]) as compared to specimens collected and transported using traditional liquid media. The study design included bench validation to demonstrate the successful recovery of target viral nucleic acids, both DNA and RNA, from the selected pathogens following stabilization on FTA Cards. The efficiency of nucleic acids recovered from FTA Cards and used in realtime PCR testing for the 4 representative BRD-associated viruses was compared to nucleic acids recovered from the traditional method of specimen collection and transport using viral transport media. The study assessed the stability of nucleic acids stored on FTA cards at a temperature range representing the extremes of environmental heat (13° to 46 °C) and cold specimen handling conditions (−7° to −27 °C), and a timeframe from specimen collection to laboratory processing consistent with the expected extremes of diagnostic sample shipping (7--14 days). For field validation, a combination of archival virus positive diagnostic specimens (*n*  = 120) and specimens collected by cooperating large animal veterinarians who were provided with the FTA Cards and minimal sampling instruction were utilized (*n*  = 81). The samples included respiratory tract specimens obtained from animals in beef herds presenting with clinical respiratory disease and consistent with current BRD herd surveillance and veterinary diagnostic practices. Archival samples included diagnostic swab fluids previously tested as realtime PCR positive for BRSV (*n*  = 30), BHV-1 (*n*  = 30), BCoV (*n*  = 30), and BVDV (*n*  = 30). Thirty virus negative archival samples were additionally tested for each of the four viruses. Samples were removed from a −70 °C freezer archive, thawed, and aliquots were spotted onto FTA cards and allowed to air-dry at room temperature. Additionally, eighty-one deep nasal swabs were collected in duplicate in the field using the traditional method of a Dacron or cotton-tipped swab, transferred into tubes of viral transport media, packaged with wet ice packs and absorbent packing materials, then shipped via overnight road delivery. The second swab collected at the same time from the same animal was transferred onto FTA Cards, allowed to air dry, and shipped in a sealed envelope ([Fig. 1](#fig0005){ref-type="fig"} ).Fig. 1Nasal swabs were obtained from 81 calves. The sampling method was nasal swabs placed in viral transport media or onto FTA Cards. Each sample was tested for the presence of 4 viruses using independent real-time PCR assays, resulting in 324 PCR tests per sample collection method.

Reference strains of the 4 BRD-associated viruses used in the study included Bovine Viral Diarrhea virus TGAC 11-14-92 kindly provided by Dr. J. Ridpath, National Animal Disease Center (NADC) in Ames, Iowa; Bovine Respiratory Syncytial Virus strain NVSL 110BVD1011; Bovine Coronavirus strain NVSL 020BDV1001; and Bovine Herpesvirus-1 stain VR-188 (Lot number 214729) obtained from the American Tissue Culture Collection. Stock virus was serially diluted from 1:10 to 1:10^−8^ in viral transport media, and stored at −70 °C prior to use. Four drops of each virus dilution were spotted onto individual Indicator FTA Cards, each drop containing approximately 20 μl of fluid. The FTA Cards were air dried at room temperature for approximately 30 min. Each specimen collected onto FTA Cards and into viral transport media was extracted and tested in triplicate by the routine realtime PCR methodology used by the California Animal Health and Food Safety Laboratory System for diagnostic sample testing. An internal control, Xeno™,[2](#fn0010){ref-type="fn"} was added prior to processing in order to evaluate the extraction efficiency from the FTA cards. The FTA Cards were processed by punching 5 mm disks from the inoculated area of 0, placing the punches in individual wells of a 96 well microtiter plate, and adding 100 μl of Rapid Extraction Solution[3](#fn0015){ref-type="fn"} to release the nucleic acids from the FTA paper. After 20 min of incubation at room temperature, the plate was shaken for 5 min at 500 rpm. Fifty microliters of fluid was transferred into a new well and the plate with the disks was discarded. From this step on, the extraction procedure was identical for the FTA Card and Viral Transport Media specimens. The MagMAX-96™ viral Isolation[4](#fn0020){ref-type="fn"} Kit was used to prepare samples for realtime PCR testing following the recommendations of the manufacturer. Real-time PCR was performed using previously published primer sets for BVDV ([@bib0050]), BHV-1 ([@bib0020]) and BRSV ([@bib0015]); the primer and probe information for BCoV was kindly provided by Dr K. Kurth (WVDL, Madison, WI). All PCR reactions utilized the Path-ID™ Multiplex One-Step RT-PCR Kit[5](#fn0025){ref-type="fn"} and were performed under the same conditions on an Applied Biosystems 7500 Fast Real-Time PCR System.[6](#fn0030){ref-type="fn"} The PCR thermocycler setting for the Path-ID™ Multiplex One-Step RT-PCR Kit was as follows: stage 1 at 50 °C for 10 min; stage 2 at 95 °C for 10 min; and stage 3 at 95 °C for 15 s; followed by stage 4 at 60 °C for 1 min; stages 3--4 were repeated for 40 cycles, whereas the commercial BVDV detection kit[7](#fn0035){ref-type="fn"} was performed per recommendation of the manufacturer. To evaluate operator variability, side-by-side testing was performed and compared between two laboratory technicians. No difference in nucleic acid recovery was detected between technicians.

The realtime PCR Ct values for the Xeno™ Internal Control provided a standard deviation of less than 0.3 cycle threshold (Ct) values, indicating consistent recovery of the viral nucleic acids from the FTA Cards. There was 100% agreement of PCR results for the FTA Card specimens and the specimens in viral transport media across all dilutions for the 4 individual viruses in the bench validation phase of the study. All virus dilution and nucleic acid recovery series showed linearity for the respective assays over at least 4 dilutions with *R* ^2^ values above 0.99. A *t*-test assessing variations among the different storage conditions revealed no statistically significant difference (*P*  ≥ 0.05) in Ct values for the range of temperature and time storage conditions for any of the 4 viruses tested. Realtime PCR efficiencies calculated within the temperature studies were above 89% for each of the 4 viruses, and linearity measurements were consistently above *R* ^2^ values of 0.92. Inter-assay variability was highest in the BVDV assay with a standard deviation of 1.5 Cts among all dilutions evaluated and lowest in the BRSV assay with a calculated standard deviation of 0.5 Cts. Agreement for the archival samples when comparing FTA-stabilized to the original swab fluid specimens was 99.58%, kappa 0.992 (95% CI = 0.975--1.0), related to a single BHV-1 discrepant specimen that was detected as positive from viral transport media and negative from the FTA Card. ([Table 1](#tbl0005){ref-type="table"}, [Table 2](#tbl0010){ref-type="table"} ). A noteworthy observation was higher Ct values indicating less viral nucleic acid detected for the archived samples on FTA cards for BRSV (average difference 6.8 Ct), BHV-1 (average difference 8.2 Ct), and BCoV (average difference 5.9 Ct). The lower detection sensitivity for FTA card samples generated from archived case material is presumed to be due to the dilution of the original swab material in viral transport media prior to archiving, as opposed to collecting directly onto FTA Cards at the time of sampling. In a recent field study (Foster et al., unpublished) 100% agreement was shown for FTA Card samples collected from nasal cavities of known BVDV PI and direct contact animals (*n*  = 69) when compared to EDTA blood from the same animals. For the field validation component of the current study where samples were collected directly onto FTA Cards prior to laboratory submission ([Fig. 1](#fig0005){ref-type="fig"}), agreement was 94.75% (307/324) based on dichotomous results (positive versus negative) comparing the specimens on FTA Cards to those in viral transport media; 4.01% (13/324) of specimens were PCR positive only using the FTA Card, and 1.23% (4/324) were positive only using the traditional viral transport media method of collection and shipping. Kappa comparison ([@bib0010], [@bib0105]) yielded a 0.779 (95% CI = 0.678--0.880) agreement (good) between the FTA Cards and the viral transport media method of sample stabilization and transport for the field sample portion of the study ([Table 2](#tbl0010){ref-type="table"}). Bovine Coronavirus was the most prevalent virus detected by realtime PCR during this phase of the study, with 60% animals testing positive (49/81). In 35 of the 49 positive animals, BCoV was detected using both sample handling approaches, in 13/49 cases only the FTA Card specimen yielded a positive result, and in 1/49 only the specimen in viral transport media tested PCR positive for BCoV. The overall agreement between the FTA Card specimens and VTM specimens in viral transport media for BCoV was 82.7% (67/81). For the remaining viruses, there was an insufficient incidence of the virus among the field specimens collected directly onto FTA Cards to statistically compare the FTA Card to the viral transport media approach to sample handling. A single specimen collected onto a FTA Card yielded a low concentration of BVDV (near the assay\'s defined limit of detection), leading to a predicted agreement of 98.76% (80/81 animals) for BVDV. Bovine Herpesvirus-1 was detected in a low concentration in two specimens in viral transport media, but not in the paired FTA specimens yielding a predicted agreement for BHV-1 of 97.53% (79/81). Bovine Respiratory Syncytial virus was detected using both the specimens in viral transport media and those on FTA Cards for 100% agreement; however the realtime PCR positive test result was for only one animal ([Table 1](#tbl0005){ref-type="table"}, [Table 2](#tbl0010){ref-type="table"}).Table 1Comparison of real-time PCR results stratified into field (*n* = 81/virus) and archived diagnostic case samples (*n* = 30 positive plus 30 negative/virus).FTA Card positiveFTA Card negativeSwab fluid positiveBRSVCoronaBHV-1BVDVBRSVCoronaBHV-1BVDVField samples135000121Archive samples30302930[\*](#tblfn9005){ref-type="table-fn"}0010Swab fluid negativeBRSVCoronaBHV-1BVDVBRSVCoronaBHV-1BVDVField samples0130080327980Archive samples000030303030[^1]Table 2Kappa values (95% CI) and percentage agreement for specimens collected into viral transport media compared to specimens collected onto FTA Cards. Table rows demonstrate overall agreement for all viruses by test sample origin; columns show overall agreement for test sample origin by individual virus.BRSVCoronaBHV-1BVDVOverall agreementField samples (*n* = 81/virus)1.00.66 (0.51--0.82)N/A[a](#tblfn0005){ref-type="table-fn"}N/A[a](#tblfn0005){ref-type="table-fn"}0.78 (0.68--0.88)100%82.72%97.53%98.76%94.75%Archive samples (*n* = 60/virus)1.01.00.97 (0.90--1.0)1.00.99 (0.98--1.0)100%100%98.33%100%99.58%Overall agreement1.00.81 (0.71--0.90)0.94 (0.87--1.0)0.98 (0.94--1.0)0.92 (0.89--0.96)100%91.49%97.87%99.29%96.99%[^2]

The study provides bench data and initial field data to support the use of FTA Card technology as a simple and efficient alternative method for diagnostic sample collection and shipment. The overall agreement between FTA Cards and viral transport media for sample handling was 0.923 (95% CI = 0.888--0.958) ([Table 1](#tbl0005){ref-type="table"}, [Table 2](#tbl0010){ref-type="table"}). The primary drawback for the use of FTA Card technology is that the sample collected cannot be used for virus isolation attempts, and is suitable only for nucleic acid-based diagnostic testing. The FTA Card approach demonstrates equivalent and potentially superior performance in delivering nucleic acids for nucleic acid-based testing, while overcoming critical sample quality drawbacks frequently associated with inconsistent cold chains, producer/practitioner on-site storage or rapid accessibility to quality laboratory transport media and supplies, and shipping concerns related to liquid biological materials. In the course of the field study, an unexpected observation was that practitioners and producers selected animals for sampling that were showing relatively advanced clinical signs of respiratory disease, apparently assuming that clinical signs equated with better diagnostic recovery of the infectious agent. In the case of BRD, as with many other disease syndromes, the inciting agent is often not detectable by the time the clinical signs are severe or even observable. This sampling observation clearly indicates that in addition to ease and convenience of the sampling tool, an equally important criterion for quality specimens must include appropriate educational efforts to ensure that specimen collection occurs in the optimum timeframe and from the animals most likely to be shedding the specific infectious agent(s) of interest.
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